Exact Sciences narrows 2Q loss

Madison-based Exact Sciences Corp., developer of a non-invasive colorectal cancer-screening test, narrowed its second quarter losses compared to the same quarter in 2012. The company showed a net loss of $12.3 million (19 cents/share) on revenues of $1 million, compared to a $14.8 million net loss (26 cents/share) on revenues of $1 million in 2012. Year to date through June, the company improved on its net loss year over year, from $25.5 million in 2012 to $23.2 million (23 cents/share) this year.